• Supreme Court Decision Removes Barrier to Importing US Patented Drug Products at Lower Cost

    This blog looks at how a recent Supreme Court decision on printer cartridges could help pave the way for wholesale drug importation. In Impression Products, Inc. v Lexmark International Inc., the Supreme Court ruled patent law cannot be used to prevent the resale of products back into the United States. The case is an important ruling in the context of the domestic policy debate concerning prescription drug pricing. Importation of prescription drugs as an antidote to the high prices in the U.S. is popular with the public and many policymakers. Read more.

  • State Wholesale Importation Program Explained

    There is growing public pressure to find an effective way to address the rising prices of prescription drugs. Among the variety of approaches aimed at managing drug prices, importation from other countries is one that comes up repeatedly. The NASHP Pharmacy Costs Work Group believes there is a way for the federal government and states to get to ‘yes’ on a program of wholesale importation. The diverse group of state officials who comprise this Work Group have developed a wholesale drug importation program that would meet the major federal law criteria that the HHS Secretary must certify in order for a program to move forward. Read the full publication.

  • Request for Proposals: State Drug Spending and Pricing Policy Initiatives

    As part of the launch of the Center for State Rx Drug Pricing, NASHP is requesting proposals from states for initiatives to develop and implement innovative approaches to contain the costs of prescription drugs. This is a multi-year project to assist state executive, legislative, and independent agencies and offices with prescription drug pricing policies. More information and to apply.

  • Update: What’s New in State Drug Pricing Legislation?

    With 80 bills introduced in 2017, there is a high level of interest in pharmaceutical pricing among state legislators. However, despite legislative sessions wrapping up, very few laws have been enacted. The latest NASHP blog examines the bills passed so far, in Maryland, Montana, New Mexico, New York, and Utah. Read the full blogpost here.

Center for State Rx Drug Pricing

The Laura and John Arnold Foundation and Kaiser Permanente funded the NASHP Pharmacy Price Work Group during 2016 that delivered a set of new state-based policy approaches, and refined and reshaped other previously proposed policies intended to constrain pharmaceutical pricing. The set of policy approaches described in “States and the Rising Costs of Pharmaceuticals: A Call to Action” has been well received by states and stakeholders.

Our task now is to facilitate the next phase of work among states wanting to move forward with these different policies. We also need to build an analytic foundation for some of the more complex, but potentially more rewarding, policy approaches that are not yet ready for implementation.

Read More

To move the state agenda forward, the Laura and John Arnold Foundation has funded NASHP to establish the NASHP Center for State Drug Price Action. The Center is staffed by Jane Horvath, who brings expertise from work both in the pharmaceutical industry and the federal government, who will direct the initiative, help  promote it with states and support state-based implementation. In brief, the Center will provide technical and strategic assistance to states, leverage legal and actuarial expertise for states as needed, distribute funding to a subset of states, and convene the Work Group to address policy and strategic issues that arise during this next phase of the project. The Center will also engage other state organizations to advance the states’ drug price policy agenda, and, lastly, disseminate learnings – successes and challenges – among states.

NASHP’s Pharmacy Costs Work Group is comprised of state leaders from governors’ staff, state legislatures, Medicaid programs, public employees, attorney generals’ offices, state-based insurance exchanges, comptrollers’ offices, and corrections departments. The group aimed to find new approaches to limit pharmaceutical costs by examining the many levers state governments have as policymakers, regulators, and purchasers.

  • Susan Barrett, J.D., Executive Director, Green Mountain Care Board
  • Burl Beasley, D.Ph., MPH, MS Pharm Clinical Pharmacist, Oklahoma Health Care Authority
  • Robert Crittenden, M.D., Senior Policy Advisor to Governor, Washington
  • James DeBenedetti Director, Plan Management Division, Covered California
  • Rebekah Gee, Secretary, Dept. of Health and Hospitals, State of Louisiana
  • Rory Griffin, Deputy Director, Arkansas Dept. of Corrections
  • Richard Gottfried, Chair, Committee on Health, New York Assembly
  • Emily Hancock, RPH, Phar. D., MPA Clinical Pharmacist, Indiana Dept. of Social and Family Services
  • Nathan Johnson, Chief Policy Officer, Washington State Health Care Authority
  • Heather Korbulic, Executive Director, Silver State Health Insurance Exchange
  • Kevin Lembo, Comptroller, State of Connecticut
  • Janet Mills, J.D., Attorney General, State of Maine
  • Rebecca Pasternik-Ikard, Chief Executive Officer, Oklahoma Health Care Authority
  • Sara Sadownik, Deputy Chief of Staff, Massachusetts Health Policy Commission
  • David Seltz, Executive Director, Massachusetts Health Care Commission
  • Norman Thurston, Ph.D., Utah State Legislature
  • Eileen Mallow, Deputy Director, WI Dept. of Employee Trust Funds
  • Linda Wiant, Chief, Medical Assistance Plans, State of Georgia
  • Josh Wojcik, Policy Director, Connecticut Office of the Comptroller
  • Trish Riley, Chair, Executive Director, NASHP

Please find information for all upcoming webinars of the Pharmacy Cost Work Group here, as well as the recordings and slide decks of previous webinars:

State policy makers interested in model legislation produced by this workgroup may request access to a legislators guide and additional background materials. Please contact Corinne Alberts if you wish to receive this state-only material.

For more information, please contact Jane Horvath, staff lead for this project.


This Resource Center was made possible with support from Laura and John Arnold Foundation and produced by NASHP Pharmacy Costs Work Group.

Latest Resources

For a full list of our Pharmaceutical Costs resources, click the Rx Center's logo below!